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Abstract
Background: For chronic pancreatitis, European prospective trials have concluded that duodenum-
preserving head resections (DPHR) are associated with less morbidity and similar pain relief and quality
of life (QoL) outcomes compared with pancreaticoduodenectomy (PD). However, DPHR procedures are
seldom performed in North America.
Methods: Patients undergoing PD or DPHR for unremitting pain secondary to chronic pancreatitis were
retrospectively identified. Quality of life was assessed cross-sectionally using the European Organization
for Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire (QLQ-C30) and pancreatic
cancer-specific supplemental module (QLQ-PAN26).
Results: Eighty-one patients underwent either a Whipple PD (n = 59) or a DPHR (Bern, Beger or Frey
procedure, n = 22) for the treatment of pain caused by chronic pancreatitis over a 5-year period. The
characteristics of patients undergoing DPHR and PD procedures were similar. Duration of procedure
(360 min vs. 245 min), duration of hospital stay (12.0 days vs. 9.5 days) and estimated blood loss (535 ml
vs. 214 ml) were all significantly less for DPHR patients (P < 0.05). Thirty-day morbidity and mortality,
postoperative pain relief and QoL scores did not differ significantly between groups.
Conclusions: Duodenum-preserving head resection is equally as effective as PD in relieving pain and
improving QoL in chronic pancreatitis patients, and involves a shorter hospital stay and less blood loss.
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Introduction
Chronic pancreatitis is a potentially debilitating disease character-
ized by recurrent abdominal pain, which leads to an altered
quality of life (QoL). Patients with chronic pancreatitis eventually
develop exocrine and endocrine insufficiency. Medical manage-
ment may temporize pain syndromes and improve digestion and
nutrition. Unfortunately, a subset of patients eventually require
surgical intervention for unremitting abdominal pain. Successful
surgical intervention can improve patients’ QoL by reducing nar-
cotic dependence and frequent hospitalizations, both of which can
limit patients’ functional status.
The exact mechanism by which chronic pancreatitis induces
pain is not known. However, surgical strategies have focused on
the resection of diseased tissue and drainage of the pancreatic
duct. Traditionally, in North American centres, the pancrea-
ticoduodenectomy (PD) has been performed for head-
predominant chronic pancreatitis, resulting in improved pain
control and QoL for many patients.1 In the past several decades,
duodenum-preserving head resections (DPHR), first described by
Beger and colleagues over 20 years ago, have gained popularity in
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Europe as an alternative surgical approach to chronic pancreati-
tis.2 Theoretically, this resection, which is limited to the diseased
organ alone, should provide a similar degree of pain relief and less
morbidity than PD. This theory has been validated in prospective
randomized trials: DPHR operations have achieved superior
pain control and improved QoL compared with standard PD
procedures and are associated with decreased perioperative
morbidity.3–5
Despite this evidence, DPHR procedures have not yet gained
widespread popularity in North America, probably as a result of
North American surgeons’ ongoing familiarity with the PD opera-
tion. This study retrospectively evaluated the surgical treatment of
chronic pancreatitis at one North American centre and compared
traditional PD with DPHR in terms of postoperative morbidity,
endocrine and exocrine function, and pain control outcomes.
Additionally, the European Organization for Research and Treat-
ment of Cancer (EORTC) quality of life questionnaire and pan-
creatic cancer module, both modified to better assess chronic
pancreatitis, were utilized to compare QoL outcomes between
patients undergoing the two types of operation.
Materials and methods
Treatment algorithm
Patients with chronic pancreatitis are treated by a multidisci-
plinary pancreas team at our centre. Those with head-
predominant disease with debilitating abdominal pain despite
maximal medical therapy are discussed as candidates for surgery
on a case-by-case basis.
During the early years of the study period (1999–2003), PD
operations were performed exclusively for head-predominant
chronic pancreatitis. From mid-2003, DPHR operations were
preferentially performed. The choice of DPHR operation (Beger,
Frey or Bern procedure) was based upon the anatomic character-
istics of the patient’s disease, such as the length and degree of
pancreatic duct stenosis and degree of fibrosis of pancreatic
parenchyma, and surgeon preference. Exceptions to this algorithm
were patients with bile duct stenosis or portal vein obstruction,
who underwent PD. Our technique for performing a PD has been
previously described.6 Duodenum-sparing resections of the pan-
creatic head were performed in a similar fashion to that described
earlier.2,7–9 Briefly, the Beger procedure consists of complete resec-
tion of the pancreatic head, sparing a rim of tissue adjacent to the
duodenum, and the completion of two pancreaticojejunostomy
anastamoses. The Frey procedure performed at our institution
consists of a coring out of the pancreatic head and lateral pancre-
atic ductotomy, followed by a single pancreaticojejunostomy. The
Bern procedure is identical to the Frey operation, but excludes the
lateral pancreatic ductotomy.
Data collection and statistical analysis
Institutional review board (IRB) approval was obtained for this
study. Our database was queried to identify patients who had
undergone PD or DPHR at the University of Cincinnati Medical
Center between September 1999 and August 2006 for the treat-
ment of chronic pancreatitis. Patients whose primary indication
for surgery was unremitting abdominal pain despite maximal
medical therapy were included in the study.
Patient charts were reviewed to obtain the following data: basic
patient characteristics; anatomic characteristics of disease; opera-
tive time; estimated blood loss; length of hospital stay; morbidity,
and mortality. Delayed gastric emptying and pancreatic leak or
fistula were identified using recently described clinical param-
eters.10,11 Re-operation excluded percutaneous intervention.
Information on QoL was collected by mailed patient question-
naires.As per IRB protocol, patients were promised confidentiality
and continuity of current medical care regardless of participation.
The EORTC QoL questionnaire (QLQ-C30,Version 3.0) and pan-
creatic cancer module (QLQ-PAN26) were used in their entirety
by permission to create the questionnaire.12 This module has been
previously validated for patients with chronic pancreatitis.13
Yes/no questions concerning current narcotic, pancreatic enzyme
and insulin usage were also included. Questionnaires were scored
by a previously validated procedure.14
sas Version 8.1 was used for statistical analysis (SAS Institute,
Inc., Cary, NC, USA). Student’s t-test analysis was used to deter-
mine significance between operative groups for the following
variables: patient age; length of symptoms; length of procedure;
estimated blood loss; follow-up time, and for QLQ-C30 and
PAN26 items. Fisher’s exact test was used to determine signifi-
cance between operative groups for the following variables:
gender; pre- and postoperative medication usage; 30-day morbid-
ity and mortality, and re-operation. Statistical differences in
length of stay were analysed using the Wilcoxon two-sample
test, and differences in aetiology were determined by chi-square
analysis.
Results
Between September 1999 and August 2006, 81 patients underwent
pancreatic head resection for chronic pancreatitis. These patients
were divided into two groups: 59 underwent a formal pancreati-
coduodenectomy (PD group) and the remaining 22 underwent
duodenal-sparing head resections (seven Bern, five Beger, 10 Frey
procedures; DPHR group). Mean follow-up time was 47 months
(range 4–87 months) in the PD group and 14 months (range 5–39
months) in the DPHR group (P < 0.01), reflecting a recent change
in our management algorithm for head-predominant chronic
pancreatitis.
There were no significant differences between operative groups
with respect to age, gender, duration of symptoms, preoperative
medication usage, aetiology or preoperatively determined ana-
tomic characteristics, as demonstrated by statistical analysis
(Table 1).
Analysis of operative data revealed higher estimated blood loss
(535 ml vs. 214 ml; P < 0.01) and longer procedure time (360 min
vs. 246 min; P < 0.01) in the PD group compared with DPHR
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patients. Duration of stay was also longer for PD patients (12.0
days vs. 9.5 days; P < 0.05). Thirty-day mortality, morbidity and
re-operation rates did not differ significantly between the PD and
DPHR groups (2/59 patients [3%] vs. 0/22 patients [0%]; 26/59
patients [44%] vs. 12/22 patients [55%]; 1/59 patients [2%] vs.
2/22 patients [9%]). Rates of occurrence of the most common
morbidities (delayed gastric emptying, wound infection and pan-
creatic leak) also did not differ between the PD and DPHR groups
(Table 2).
Overall, 39 patients (48% of total) returned questionnaires,
including 27 in the PD group (46%) and 12 in the DPHR group
(55%). Six patients (7%) were lost to follow-up and another six
(7%) were confirmed dead. Of note, two patients in the PD group
and one in the DPHR group did not complete the questions
regarding medication use.
No significant differences in postoperative medication use were
found between the groups. In the PD group, nine of 25 (36%)
patients required insulin, compared with two of 11 (18%) patients
in the DPHR group (P = NS). Similar rates of pancreatic enzyme
and narcotic use were found between the PD and DPHR groups
(18/25 patients [73%] vs. 9/11 patients [82%], P = NS; 16/25
patients [65%] vs. 6/11 patients [55%], P = NS) (Table 3).
Table 1 Characteristics of study population
PD group (n = 59) DPHR group (n = 22) P-value
Age, years, mean  SD 46.8  11.1 44.9  11.1 NS
Gender, male/female 26/33 8/14 NS
History of symptoms, years, mean  SD 5.4  6.2a 6.1  6.1a NS
Preoperative medications, n (% of patients)
Narcotics 50 (84%) 18 (82%) NS
Pancreatic enzymes 27 (45%) 8 (36%) NS
Insulin 4 (7%) 2 (9%) NS
Aetiology, n (% of patients)
Ethanol 26 (44%) 8 (36%) NS
Idiopathic 23 (39%) 8 (36%) NS
Pancreas divisum 7 (12%) 5 (23%) NS
Biliary 3 (5%) 3 (14%) NS
Anatomic characteristics, n (% of patients)
Pancreatic duct stenosis 41 (69%) 17 (77%) –
Bile duct stenosis 21 (36%) 5 (23%) –
Preoperative stent 15 (25%) 4 (17%) –
Jaundice 2 (3%) 0 (0%) –
Pseudocyst 9 (15%) 5 (23%) –
Pancreatic head mass 4 (7%) 1 (5%) –
Portal vein thrombosis 0 (0%) 0 (0%) –
an = 36 in PD group, n = 18 in DPHR group
PD, pancreaticoduodenectomy; DPHR, duodenum-preserving head resection; SD, standard deviation; NS, non-significant
Table 2 Operative characteristics and postoperative course
PD group (n = 59) DPHR group (n = 22) P-value
Duration of procedure, min, mean  SD 360  119a 246  72a P < 0.01
Estimated blood loss, ml, mean  SD 535  544 214  327 P < 0.01
Duration of stay, days, median (range) 12.0 (9.8–14.2) 9.5 (3.3–15.7) P < 0.05
30-day mortality, n (% of patients) 2 (3%) 0 (0%) NS
30-day morbidity, n (% of patients) 26 (44%) 12 (55%) NS
Delayed gastric emptying 9 (15%) 1 (5%) NS
Wound infection/dehiscence 6 (10%) 5 (23%) NS
Pancreatic leak/fistula 4 (7%) 3 (14%) NS
30-day re-operation, n (% of patients) 1 (2%) 2 (9%) NS
an = 58 in PD group, n = 20 in DPHR group
PD, pancreaticoduodenectomy; DPHR, duodenum-preserving head resection; SD, standard deviation; NS, non-significant
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Responses to the QLQ-C30 and QLQ-PAN26 questions were
grouped into the pre-defined six functional scales (including
global QoL) and 26 symptom scales (including 16 single items).
Student’s t-test comparing mean values for the operative groups
revealed statistically significant differences on only two symptom
scales. For both, higher symptomatology was seen in the PD group
compared with the DPHR group (diarrhoea: 50.0 vs. 23.2, P <
0.05; dry mouth: 40.7 vs. 18.2, P < 0.05). Although not significant,
higher symptomatology was observed in the PD group on 23 of 24
additional symptom scales, and lower QoL was observed in the PD
group on five of six functional scales (Table 4).
Discussion
In North America, the PD procedure has remained the standard
operation for surgical treatment of chronic pancreatitis. Multiple
retrospective reviews have demonstrated this operation to have
become increasingly safe, with mortality rates of about 2%.1,15
Because of the chronic debilitating nature of pancreatitis, postop-
erative complications, most commonly sepsis, delayed gastric
emptying, pancreatic fistula and wound infection, are relatively
common, occurring in about 33% of patients, and length of
hospital stay averages 14–20 days.1,15 However, PD is effective,
eliminating or significantly improving pain in 75–100% of
patients.1,15,16
Over the past 20 years, DPHR procedures, originally described
by Beger and later modified into the Frey and Bern operations,
have gradually replaced PD as standard surgical treatment for
head-predominant chronic pancreatitis in European centres. A
large, single-centre retrospective review of 504 Beger procedures
performed over 26 years demonstrated a postoperative mortality
of <1%, and the elimination of pain in ~ 90% of patients at both
2 and 5 years postoperatively; these results indicate the equiva-
lence of the Beger and PD operations in the treatment of chronic
pancreatitis.17 Several prospective trials comparing each DPHR
operation with PD have produced similar results.3–5,16,18–19 In these
trials, the DPHR has been associated with significantly shorter
procedure time,4,5 decreased postoperative morbidity4,5 and
shorter length of stay5,19 than PD. In trials in which DPHR and PD
were compared directly, longterm pain control was significantly
better in DPHR patients, compared with PD patients, in three of
five studies.3,16,19 Similarly, significantly better weight gain was
seen in DPHR patients in three of four trials.3,5,19 Quality of life,
measured by the EORTC QoL questionnaire, although improved
from baseline at 24 months and 63 months in both groups, was
significantly better in DPHR patients at both postoperative
time-points.16,19 None of these trials has shown DPHR to be
significantly inferior to PD in any of the parameters mentioned,
which suggests that DPHR represents a superior operation for
chronic pancreatitis.
Despite this evidence, DPHR procedures have not yet gained
widespread popularity among US surgeons. In one recent survey
of pancreatic surgeons at academic medical centres, only 23 of 59
surgeons operating for chronic pancreatitis stated that they cur-
rently performed DPHR operations.13 Further, 76% of pancreas
surgeons who had never performed a DPHR cited either inad-
equate evidence to support the effectiveness of DPHR or the
superiority of PD and the Puestow procedure as their reason for
not having performed the surgery.13 Only three retrospective
studies, including ours, have been performed in North America
to assess outcomes following DPHR: Aspelund and colleagues
reported decreased morbidity in patients undergoing a Frey
procedure compared with those undergoing PD for benign
indications, and Varghese and Bell demonstrated significantly
improved pain levels and digestive function after DPHR com-
pared with controls with pancreatitis.13,20 We sought to confirm
the European results by demonstrating the equivalence of DPHR
to PD in terms of both short-term morbidity and mortality and
patient QoL.
Our selection criteria for operative intervention were similar to
those described in the European prospective trials: severe abdomi-
nal pain caused by chronic pancreatitis with preoperative
abdominal computed tomography (CT) or endoscopic retro-
grade cholangiopancreatography (ERCP) diagnostic of head-
predominant disease. Interestingly, in all the European trials,
pancreatic head enlargement (usually defined as >4 cm) was
present in nearly all patients; in some trials, head enlargement was
an inclusion criterion.3–5,14–17 This finding was noted specifically by
preoperative imaging in <10% of our patients. This disparity
probably reflects a difference in diagnostic workups; at our centre,
all patients with head masses visualized on initial imaging
undergo thin-cut helical CT and endoscopic ultrasound to
attempt to distinguish inflammatory from malignant lesions in
order to guide operative planning, but this preoperative workup
may be less prominent in European algorithms. This difference
may also reflect a change in operative management of chronic
Table 3 Comparison of postoperative medications
PD group (n = 25) DPHR group (n = 11) P-value
Insulin, n (% of patients) 9 (36%) 2 (18%) NS
Pancreatic enzymes, n (% of patients) 18 (73%) 9 (82%) NS
Narcotics, n (% of patients) 16 (65%) 6 (55%) NS
Follow-up time, months 47  20a 14  8a P < 0.01
an = 59 in PD group, n = 22 in DPHR group
PD, pancreaticoduodenectomy; DPHR, duodenum-preserving head resections; NS, non-significant
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pancreatitis, in which head enlargement is no longer required as
an indication for surgical intervention.
The 30-day morbidity rates did not differ significantly between
the PD (44%) and DPHR (55%) groups and are similar to those
reported in previous series. Rates of delayed gastric emptying and
pancreatic leak also did not differ significantly between groups, or
compared with prior studies. Rates of postoperative wound infec-
tion have been less frequently reported. However, our wound
infection and dehiscence rate in the PD population (10%) is con-
sistent with that reported in one prior study.4 Of note, all of the
patients in this group had undergone ERCP with stent placement
preoperatively, a known risk factor for the development of wound
infection. In the DPHR group, the rate was somewhat higher
(23%), although this difference was not statistically significant,
probably as a result of the small sample size. Three of the five
patients in this group who developed wound infections had
undergone prior endoscopic intervention; two of the patients
required re-laparotomy for other indications following initial
operation and developed wound infections after re-operation.
A total of 36% of patients in the PD group and 18% in the
DPHR group required insulin postoperatively; this difference was
not significant. In both groups, several patients who had not had
Table 4 Postoperative quality of life assessment
PD group (n = 27) DPHR group (n = 12) P-value
Functional Scales, mean  SD
Physical status 67.5  32.3 67.2  34.4 NS
Working ability 50.6  41.2 56.9  41.1 NS
Cognitive functioning 56.8  32.1 68.1  38.6 NS
Emotional functioning 48.4  32.6 62.5  26.7 NS
Social functioning 50.6  36.5 54.2  40.3 NS
Global quality of life 48.8  29.3 52.8  30.8 NS
Symptom Scales, mean  SD
Fatigue 56.8  31.2 48.1  36.5 NS
Nausea and vomiting 43.8  36.7 27.8  41.6 NS
Pain 56.8  38.5 54.2  34.2 NS
Dyspnoea 32.0  37.9 22.2  32.8 NS
Insomnia 58.7  40.0 52.8  43.7 NS
Appetite loss 51.3  39.1 33.3  37.6 NS
Constipation 24.7  32.8 16.7  30.2 NS
Diarrhoea 50.0  36.8 23.2  32.8 P < 0.05
Financial difficulties 59.3  36.2 52.8  43.7 NS
Pancreas-specific pain 54.0  28.6 43.7  31.6 NS
Diet restriction 62.8  38.3 51.4  37.2 NS
Jaundice and pruritus 16.7  22.2 15.2  13.9 NS
Steatorrhoea 56.2  33.7 37.9  32.6 NS
Poor body image 56.8  44.2 34.8  32.9 NS
Sexual dysfunction 66.0  36.5 55.6  40.8 NS
Dissatisfaction with care 64.1  32.6 63.3  32.2 NS
Bloating 50.7  35.0 41.7  37.9 NS
Bad-tasting food 28.4  34.2 30.6  38.8 NS
Indigestion 40.7  31.1 30.0  27.7 NS
Flatulence 61.7  35.5 45.5  37.3 NS
Difficulty gaining weight 39.5  44.4 27.3  41.7 NS
Weakness 55.6  35.8 48.5  43.1 NS
Dry mouth 40.7  32.5 18.2  27.3 P < 0.05
Treatment side-effects 59.3  32.5 48.5  34.5 NS
Worry about future 77.5  31.8 60.6  29.1 NS
Difficulty planning 54.3  39.4 36.4  43.3 NS
PD, pancreaticoduodenectomy; DPHR, duodenum-preserving head resection; SD, standard deviation; NS, non-significant
HPB 681
HPB 2009, 11, 677–683 © 2009 International Hepato-Pancreato-Biliary Association
diabetes preoperatively required insulin after surgery. Although
one prior study demonstrated significantly higher average blood
glucose levels in patients following PD surgery, compared with
those undergoing DPHR, no other trials have demonstrated
higher rates of diabetes in either group.3 The majority of our
patients (73% PD, 82% DPHR) continued use of pancreatic
enzymes postoperatively; similarly, 60–90% of patients in
other trials demonstrated exocrine insufficiency after either
procedure.3–5
The EORTC QLQ-C30 and pancreatic cancer module (QLQ-
PAN 26) were utilized to evaluate QoL in our patient populations.
The QLQ-C30 has been used previously to measure postoperative
outcomes in patients with chronic pancreatitis4,18–19; more
recently, the QLQ-PAN 26, originally designed for pancreas cancer
patients, was also validated as a reliable tool to evaluate the symp-
toms of chronic pancreatitis.12,21 Previous studies have demon-
strated postoperative improvement in QoL after both PD and
DPHR operations, compared with preoperative scores.4,18 Our PD
patients achieved similar QoL scores postoperatively, with a mean
follow-up time of 47 months. By contrast, our DPHR patients had
somewhat worse QoL outcomes on both the functional and
symptom-based scales compared with patients in prior studies
who had undergone these procedures. This may reflect the length
of follow-up, which averaged only 13 months in our population,
compared with 24–60 months in the prior studies.4,18–19 In one
prior study population, significantly better postoperative QoL
outcomes were demonstrated following DPHR compared with
PD, at both 2- and 5-year follow-up time-points.16,19 Interestingly,
our DPHR population demonstrated higher functional scores on
five of six scales, and lower symptom scores on 25 of 26 scales,
compared with PD patients, even with a significantly shorter
follow-up period.Although only two symptom scales were signifi-
cantly better in DPHR patients, this trend suggests that significant
differences may be present and may be more apparent in future
studies evaluating larger populations of patients with longer
follow-up times.
In this study, we assessed postoperative pain control by ques-
tioning patients’ narcotic use at the time of questionnaire comple-
tion, and as part of the QLQ-C30 and PAN 26 QoL symptom
scales. In a few prior studies, DPHR procedures were demon-
strated to be superior to PD in achieving relief from pancreatitis-
related pain; in most others, the procedures are equivalent.3,19,22 In
current series, about 60% of patients are pain-free at longterm
follow-up and 20–30% continue to experience occasional to fre-
quent pain.3,19,22 Although we did not directly assess frequency of
pain in our population, both our indicators suggest that patients
in both our PD and DPHR groups had worse pain outcomes than
those previously reported. On the QLQ-C30 scale, our pain
symptom scores were 54 and 56 in the DPHR and PD groups,
respectively, compared with scores of 19–36 reported in prior
studies.16,19 Opioid use has been reported to be about 20% in
longterm follow-up after either procedure; 55% and 65% of our
patients continued to use narcotics after DPHR and PD, respec-
tively.22 Several reasons may account for or contribute to this
disparity. Firstly, a recent retrospective review by Reidiger et al.
found both follow-up time <5 years and preoperative duration of
symptoms <8 years to be associated with the occurrence of more
frequent pain by regression analysis.22 These findings may par-
tially explain our poor results among DPHR patients (mean
follow-up time 14 months, preoperative duration of symptoms
6.1 years), although previous trials achieved their superior results
with follow-up times similar to ours. Secondly, our study does not
assess factors that probably contribute to narcotic use in our
patient population, such as the frequency or severity of recurrent
attacks of acute pancreatitis, continued ethanol abuse and nar-
cotic dependence or abuse. Our questionnaire also does not estab-
lish whether patients have ever achieved pain control without
narcotics postoperatively and nor does it inquire about the spe-
cific indications for narcotic use. It is likely that more specific
questions evaluating these factors might have helped us to better
characterize patients’ pain experiences and details of their narcot-
ics usage, and to achieve results more similar to those previously
reported. Lastly, the relatively small sample size and retrospective
nature of our study, compared with the large European prospec-
tive trials, may account for the differences in pain outcome we
observed.
In conclusion, the DPHR and PD procedures are equally effec-
tive in improving QoL and pain relief for patients with chronic
pancreatitis. These findings are similar to those demonstrated
repeatedly in European trials, but this is the first trial to replicate
these results in a North American series. Furthermore, the DPHR
outcomes were achieved with significantly shorter operating times
and less intraoperative blood loss than PD.Duodenum-preserving
head resections should be considered as equivalent alternatives to
PD in the surgical treatment of chronic pancreatitis. Amulticentre
prospective trial in North America may provide more evidence to
this end and may help to increase the popularity of these opera-
tions on this continent. Regardless, a more widespread adoption
of these procedures should be encouraged in North American
centres.
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